Critical Comparison: Coeptis Therapeutics (NASDAQ:COEP) versus Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zura Bio and Coeptis Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0	0	5	1	3.17
Coeptis Therapeutics	0	0	1	0	3.00

Zura Bio currently has a consensus price target of $18.00, suggesting a potential upside of 289.61%. Coeptis Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 733.33%. Given Coeptis Therapeutics’ higher probable upside, analysts clearly believe Coeptis Therapeutics is more favorable than Zura Bio.

Insider & Institutional Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 15.8% of Zura Bio shares are owned by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Zura Bio and Coeptis Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$69.24 million	N/A	N/A
Coeptis Therapeutics	$80,000.00	162.41	-$21.27 million	($0.84)	-0.43

Coeptis Therapeutics has higher revenue and earnings than Zura Bio.

Profitability

This table compares Zura Bio and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-82.30%	-66.71%
Coeptis Therapeutics	N/A	-794.75%	-322.86%

Risk and Volatility

Zura Bio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500.

Summary

Zura Bio beats Coeptis Therapeutics on 7 of the 11 factors compared between the two stocks.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.